Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)

被引：0
|
作者：
Xiang Zhang
Lotte C. A. Stiekema
Erik S. G. Stroes
Albert K. Groen
机构：
[1] Amsterdam University Medical Center,Department of Experimental Vascular Medicine
[2] University of Amsterdam,Human and Animal Physiology
[3] Wageningen University,Department of Vascular Medicine
[4] Amsterdam University Medical Center,undefined
[5] University of Amsterdam,undefined
来源：
Lipids in Health and Disease | / 19卷
关键词：
PCSK9 antibodies; Evolocumab; Lipoprotein(a); Metabolomics; VLDL;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] PCSK9 inhibition in patients with hypercholesterolemia
    Desai, Nihar R.
    Sabatine, Marc S.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2015, 25 (07) : 567 - 574
  • [32] PCSK9 Inhibition and Oxidized Phospholipids
    Bhatia, Harpreet S.
    Yeang, Calvin
    Baruch, Amos
    Yang, Xiaohong
    Stroes, Erik S. G.
    Tsimikas, Sotirios
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (12) : 1288 - 1289
  • [33] Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
    Raal, Frederick J.
    Giugliano, Robert P.
    Sabatine, Marc S.
    Koren, Michael J.
    Langslet, Gisle
    Bays, Harold
    Blom, Dirk
    Eriksson, Mats
    Dent, Ricardo
    Wasserman, Scott M.
    Huang, Fannie
    Xue, Allen
    Albizem, Moetaz
    Scott, Rob
    Stein, Evan A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (13) : 1278 - 1288
  • [34] Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
    Rosenson, Robert S.
    Jacobson, Terry A.
    Preiss, David
    Djedjos, C. Stephen
    Dent, Ricardo
    Bridges, Ian
    Miller, Michael
    CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (03) : 305 - 313
  • [35] PCSK9 Inhibition The Next Statin?
    Vogel, Robert A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (25) : 2354 - 2355
  • [36] New prospects for PCSK9 inhibition?
    Landmesser, Ulf
    Chapman, M. John
    Stock, Jane K.
    Amarenco, Pierre
    Belch, Jill J. F.
    Boren, Jan
    Farnier, Michel
    Ference, Brian A.
    Gielen, Stephan
    Graham, Ian
    Grobbee, Diederick E.
    Hovingh, G. Kees
    Luscher, Thomas F.
    Piepoli, Massimo F.
    Ray, Kausik K.
    Stroes, Erik S.
    Wiklund, Olov
    Windecker, Stephan
    Luis Zamorano, Jose
    Pinto, Fausto
    Tokgozoglu, Lale
    Bax, Jeroen J.
    Catapano, Alberico L.
    EUROPEAN HEART JOURNAL, 2018, 39 (27) : 2600 - 2601
  • [37] Inhibition of PCSK9 in familial hypercholesterolaemia
    Sijbrands, Eric J. G.
    LANCET, 2012, 380 (9836): : 6 - 7
  • [38] PCSK9 inhibition: A promise fulfilled?
    White, Khendi
    Mohan, Chaitra
    Rocco, Michael
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2016, 83 : S36 - S44
  • [39] Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
    Robert S. Rosenson
    Terry A. Jacobson
    David Preiss
    C. Stephen Djedjos
    Ricardo Dent
    Ian Bridges
    Michael Miller
    Cardiovascular Drugs and Therapy, 2016, 30 : 305 - 313
  • [40] Effects of Long-term, Monthly Administration of the Pcsk9 Inhibitor Evolocumab (Amg 145) in Patients with Dysglycemia or Metabolic Syndrome
    Henry, R. R.
    Holman, R. R.
    Giugliano, R. P.
    Raal, F. J.
    Sullivan, D.
    Honarpour, N.
    Nelson, P.
    Elliott, M.
    Liu, T.
    Wasserman, S. M.
    Somaratne, R.
    Koren, M. J.
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2014, 21 : S8 - S8
12345